Answers are grounded in this paper and cite their sources.
Describe the design of a phase 2 study (NCT05642442) of a once-daily, extended-release formulation of suvecaltamide to treat moderate to severe residual Parkinson's disease tremor (PDT).
No takes yet. Share an insight, caveat, or question.
Skarpaas et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: